TRIP13

Across TCGA pan-cancer cohorts, TRIP13 RNA differs between tumor and matched normal tissue in 16 of 18 cancer types tested, making tumor–normal expression one of TRIP13’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where TRIP13 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TRIP13 is over-expressed in tumor.

KIRC, LUAD, and BLCA are the cancer types where TRIP13 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TRIP13 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	IV	+1.440	<.001	12	view →
LUAD	Male	III,IV	+2.990	<.001	11	view →
BLCA	Male	All	+2.735	<.001	11	view →
HNSC	Male	All	+2.595	<.001	11	view →
COAD	Female	II,III,IV	+2.405	<.001	11	view →
KIRP	All	III,IV	+1.832	<.001	11	view →
STAD	Female	All	+2.861	<.001	9	view →
LIHC	Male	All	+1.613	<.001	9	view →
LUSC	Female	All	+3.739	<.001	8	view →
READ	All	All	+1.968	<.001	7	view →
THCA	All	III,IV	+0.418	.001	7	view →
UCEC	All	III,IV	+2.842	<.001	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 16 lineages.

TRIP13–KIRC

Open the KIRC breakdown →